Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ARMP 
Armata Pharmaceuticals Inc (ARMP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: ARMP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -73.1% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 69.85M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 495270 | Beta 0.97 | 52 Weeks Range 0.90 - 3.42 | Updated Date 06/21/2025 |
52 Weeks Range 0.90 - 3.42 | Updated Date 06/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.4 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -9.07% | Operating Margin (TTM) -1668.23% |
Management Effectiveness
Return on Assets (TTM) -24.32% | Return on Equity (TTM) -3439.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 192823414 | Price to Sales(TTM) 14.87 |
Enterprise Value 192823414 | Price to Sales(TTM) 14.87 | ||
Enterprise Value to Revenue 148.14 | Enterprise Value to EBITDA 14.3 | Shares Outstanding 36193500 | Shares Floating 11019467 |
Shares Outstanding 36193500 | Shares Floating 11019467 | ||
Percent Insiders 69.59 | Percent Institutions 2.05 |
Analyst Ratings
Rating 4 | Target Price 9 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Armata Pharmaceuticals Inc
Company Overview
History and Background
Armata Pharmaceuticals Inc. is a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant infections. Founded in 2003 (as AmpliPhi Biosciences), it has evolved through acquisitions and strategic shifts to focus on phage therapy.
Core Business Areas
- Bacteriophage Therapeutics: Development and commercialization of bacteriophage-based therapies targeting antibiotic-resistant bacteria. Focus on difficult-to-treat infections.
Leadership and Structure
The leadership team consists of experienced professionals in biotechnology and pharmaceuticals. The company operates with a structure typical of a clinical-stage biotech company.
Top Products and Market Share
Key Offerings
- R&D Pipeline: Armata's lead product candidates are in clinical development for various bacterial infections. While there is no current market share for approved products, the potential addressable market for antibiotic-resistant infections is significant. Competitors include companies developing novel antibiotics and other antimicrobial therapies. No current revenue data is available, as the company is pre-revenue. Competitors include Adaptive Phage Therapeutics and BiomX.
Market Dynamics
Industry Overview
The industry is characterized by a growing need for novel antibiotics and alternative antimicrobial therapies due to the rise of antibiotic-resistant bacteria. The bacteriophage therapy market is emerging, with increasing interest from researchers and investors.
Positioning
Armata is positioned as a leader in the bacteriophage therapy space, with a focus on developing targeted therapies for specific bacterial infections. Competitive advantages include its phage library and expertise in phage engineering.
Total Addressable Market (TAM)
The estimated global TAM for antimicrobial resistance solutions is over $10 billion and is expected to grow in the coming years. Armata aims to secure a piece of this market through its bacteriophage therapies.
Upturn SWOT Analysis
Strengths
- Proprietary phage library
- Expertise in phage engineering
- Focus on targeted therapies
- Potential to address antibiotic resistance
Weaknesses
- Limited financial resources
- Clinical trial risks
- Regulatory hurdles
- Dependence on successful clinical outcomes
Opportunities
- Partnerships with pharmaceutical companies
- Government funding for antimicrobial resistance
- Expansion into new bacterial infections
- Increasing awareness of phage therapy
Threats
- Competition from other antimicrobial therapies
- Clinical trial failures
- Regulatory delays
- Development of resistance to phages
Competitors and Market Share
Key Competitors
- APT
- BMRA
- AEMD
Competitive Landscape
The competitive landscape is evolving. Armata's advantages include its phage library and targeted therapy approach. Disadvantages include limited financial resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the pre-revenue stage. The growth trajectory depends on successful clinical development and commercialization.
Future Projections: Future growth projections depend on analyst estimates and are highly dependent on clinical milestones. These are subject to change, as such, consult with a financial expert.
Recent Initiatives: Recent strategic initiatives include advancing clinical trials, securing funding, and exploring partnerships.
Summary
Armata Pharmaceuticals is a clinical-stage biotech company focused on developing phage therapies. The company's strength lies in its proprietary phage library and targeted approach to address antibiotic resistance. However, it faces financial constraints and clinical trial risks. Successful clinical outcomes are key for future growth and market penetration.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data is based on publicly available information and is subject to change. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Armata Pharmaceuticals Inc
Exchange NYSE MKT | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2011-03-09 | CEO & Director Dr. Deborah L. Birx M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 60 | Website https://www.armatapharma.com |
Full time employees 60 | Website https://www.armatapharma.com | ||
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.